Business
Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
Summit Therapeutics plc(‘Summit' or the 'Company')Summit's Pipeline Expands with Series of New Mechanism Antibiotics Targeting EnterobacteriaceaeData to be
About this update from Summit Therapeutics Inc.
[{"type":"text","content":"Summit Therapeutics plc(‘Summit' or the 'Company')Summit's Pipeline Expands with Series of New Mechanism Antibiotics Targeting EnterobacteriaceaeData to be Presented in Oral Session at ECCMID 2019Oxford, UK, and Cambridge, MA, US, 3 April 2019 - Summit Therapeutics plc (NASDAQ: SMMT, AIM:SUMM), a leader in new mechanism antibiotic innovation, today announces the expansion of its pipeline with a series of new mechanism antibiotics, DDS-04, which targets Enterobacteriaceae. Key data from this series will be presented in an oral session at the 29thEuropean Congress of Clinical Microbiology & Infectious Diseases (‘ECCMID'), taking place 13-16 April 2019 in Amsterdam.\"The DDS-04 series provides us with a major opportunity to improve patient outcomes across several body sites where Enterobacteriaceae cause infection,\" said Dr David Roblin, President of R&D of Summit. \"We look forward to developing the programme to show compelling clinical and economic data that offer significant advantages over standard of care for the patients in need.\" Summit's DDS-04 series of new mechanism antibiotic compounds acts specifically on Enterobacteriaceae via LolCDE, an unexploited bacterial target. It is the first project to emerge from the Company's ESKAPE pathogen programme. Enterobacteriaceae are a family of Gram-negative bacteria, which include the critical threats Klebsiella pneumoniae and Escherichia coli. These bacteria are responsible for a large number of severe and often deadly infections of the bloodstream, lungs and urinary tract. The DDS-04 series has shown activity across a global panel of K.pneumoniae and E. coli strains, including strains resistant to current standard of care treatments.Details of the presentation are as follows:Date:14 April 2019Time: 1:42pm CESTSession: Novel antimicrobial agents and discovery strategiesLocation: Hall MTitle:Novel Small-Molecule Inhibitors of Bacterial Lipoprotein Transport with Potent Antimicrobial Activity against EnterobacteriaceaeAuthors: E. Breidenstein, O. Abdulle, T. Avis, C. Charrier, C. Ciardullo, C. Coward, T. Duffy, N. Khan, C. Mason, P. Meo and D. PowellAbout EnterobacteriaceaeEnterobacteriaceae are a family of Gram-negative bacteria responsible for a large number of severe and often deadly infections of the bloodstream, lungs and urinary tract. Increasing resistance of Enterobacteriac...